CJC-1295 without DAC 5mg + IPA 5mg

Description

Strength: 10mg
CAS: CJC-1295: 863288-34-0 Ipamorelin: 170851-70-4
Chemical Formula: CJC-1295 No DAC: C₁₅₂H₂₅₂N₄₄O₄₂ Ipamorelin: C₃₈H₄₉N₉O₅
Molecular weight: Ipamorelin: 711.85296 g/mol MOD-GRF(1-29) CJC1295 No DAC: 33367.954 g/mol
Peptide Sequence: Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2 MOD-GRF(1-29) CJC-1295 No DAC: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
Synonyms: Ipamorelin Acetate, IPAM, NNC-26-0161 MOD-GRF(1-29), CJC-1295 without DAC, modgrf
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.

This combination is studied to examine how growth hormone secretion is stimulated through two distinct signaling pathways:

• CJC-1295 without DAC: Acts as a GHRH receptor agonist, activating adenylyl cyclase and cAMP-dependent pathways on pituitary somatotrophs
• Ipamorelin: Acts as a GHRP-receptor agonist (GHS-R agonist) through calcium-dependent signaling mechanisms, demonstrating selectivity for GH release without affecting ACTH or cortisol levels

The synergistic combination leverages complementary mechanisms: cAMP activation (CJC-1295) and calcium-dependent signaling (Ipamorelin) to produce amplified GH secretion through multi-pathway activation.

• High-purity peptides provided in separate 5 mg vials for precise dosing in research.
• Lyophilized powder form for enhanced stability and easy reconstitution.
• Synergistic Functionality: Combines two peptides that stimulate growth hormone through different receptors.
• Metabolic Regulation: Used in studies exploring endogenous growth hormone stimulation.
• Cellular Impact: Supports research on tissue repair, cell regeneration, and recovery.
• Stable when stored correctly at low temperatures.

This combination is used to study how growth hormone secretion is stimulated through two distinct pathways. CJC-1295 acts like GHRH, while Ipamorelin activates ghrelin receptors.

Research explores the peptides’ roles in metabolic regulation, tissue growth, and endocrine modulation, with a focus on muscle and bone biology and potential applications in aging-related processes.

In preclinical and laboratory studies, dosing protocols for CJC-1295 without DAC and Ipamorelin combinations typically employ:

• CJC-1295 without DAC: 100–300 mcg per injection, administered 2–3 times daily to maintain elevated GH levels (short 30-minute half-life)​
• Ipamorelin: 200–300 mcg per injection, administered daily or 2–3 times daily depending on study protocol​
• Combination approach: Both peptides are often co-administered to maximize synergistic GH release through dual-pathway activation​

Published single-dose rodent studies have evaluated CJC-1295 at 30–60 µg/kg; however, sustained research applications typically use the absolute dosages listed above.​

Research observations include:

• Elevated growth hormone (GH) levels with enhanced pulsatility​
• Increased insulin-like growth factor 1 (IGF-1) production
• Enhanced tissue repair and recovery markers
• Preserved hormone selectivity (ipamorelin does not increase ACTH or cortisol)​

These observations are based on animal studies, and there is no clinical data on human dosing or safety/efficacy.​

• Storage: Store lyophilized peptides at –20°C or below in a dry, light-protected
• After reconstitution, store at 2–8°C and use within 5–7 days.
• Avoid freeze-thaw cycles to protect peptide integrity.
• Handle using aseptic techniques and proper laboratory safety protocols.

References

https://pmc.ncbi.nlm.nih.gov/articles/PMC11426299/

https://pmc.ncbi.nlm.nih.gov/articles/PMC9223426/

https://www.nature.com/articles/s41392-022-00904-4

https://www.ncbi.nlm.nih.gov/books/NBK562260/

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.